中国典型病例大全

目的 分析在急性心肌梗死（acute myocardial infarction,AMI）患者急诊经皮冠状动脉介入治疗（percutaneous coronary intervention,PCI）术后心力衰竭中应用达格列净联合沙库巴曲缬沙坦钠的临床疗效。方法 回顾性分析2022年1月—2023年5月吉化集团公司总医院二院心内科收治的80例PCI术后心力衰竭患者的基本资料，根据入院先后顺序分组，2022年1—8月入院的40例患者设为对照组，应用沙库巴曲缬沙坦钠治疗；2022年9月—2023年5月入院40例患者设为观察组，应用达格列净+沙库巴曲缬沙坦钠治疗。对比两组临床疗效、心功能指标。结果 对照组治疗总有效率低于观察组（P<0.05）；治疗后，观察组心功能指标优于对照组（P<0.05）。结论 达格列净+沙库巴曲缬沙坦钠应用于急性心肌梗死患者急诊经皮冠状动脉介入治疗术后心力衰竭中，能够改善临床疗效和心功能指标，促进预后，值得推广。

Objective To analyze the clinical efficacy of dapagliflozin combined with sacubitril valsartan sodium in emergency percutaneous coronary intervention(PCI)for postoperative heart failure in patients with acute myocardial infarction(AMI). Methods A retrospective analysis was conducted on the basic data of 80 patients with heart failure after PCI admitted to the cardiology department of the Second Hospital of Jihua Group Corporation from January 2022 to May 2023. According to the order of admission, 40 patients were admitted between January and August 2022 and treated with sacubitril valsartan sodium as the control group; Forty patients admitted between September 2022 and May 2023 were treated with dapagliflozin and sacubitril valsartan sodium as the observation group. Compare the clinical efficacy and cardiac function indicators between two groups.Results The total effective rate of the control group was lower than that of the observation group(P<0.05); The cardiac function indicators of the observation group were better than those of the control group after treatment(P<0.05). Conclusion The application of dapagliflozin+sacubitril valsartan sodium in emergency percutaneous coronary intervention for postoperative heart failure in patients with acute myocardial infarction can improve clinical efficacy and cardiac function indicators, promote prognosis, and is worthy of promotion.